April 28, 2026
Gleason Score Explained
A positive prostate biopsy leads to many questions that most men have never had to ask before. What does the cancer look like? How fast is it growing? Do I need treatment right now? Nearly every answer your urologist gives will trace back to a single number: your Gleason score.
Understanding what that number actually means, not just whether it sounds high or low, is one of the most useful things you can do in the days following a diagnosis. This blog discusses how the Gleason grading system works, what each score range means clinically, what the research says about life expectancy at each grade, and how to use all of it to have a more informed conversation with your care team.
What Is a Gleason Score?
The Gleason score is a pathological grading system that measures how aggressive prostate cancer cells appear under a microscope. The scoring process works like this: a pathologist examines biopsy tissue samples and assigns a pattern grade from 1 to 5 to each of the two most prevalent cancer cell patterns present. Grade 1 and 2 cells closely resemble normal prostate tissue. Grade 5 cells are highly abnormal, disorganized, and associated with rapid aggressive growth. The two grades are then added together to produce the final Gleason score, a sum that can theoretically run from 2 to 10, though scores below 6 are not considered cancerous in modern practice.
The notation carries as much information as the sum itself. A Gleason score of 3+4=7 and a score of 4+3=7 produce the same total, but they represent meaningfully different cancers with different prognoses. The first number always reflects the dominant pattern, the one present in the greatest volume of tissue, and that distinction can change the entire direction of the treatment conversation.
The Gleason Score Chart
Gleason scores in clinical practice run from 6 to 10, corresponding to five Grade Groups and four risk tiers. Here is how they map:
| Gleason Score | Grade Group | Risk Category |
|---|---|---|
| 6 (3+3) | GG1 | Low |
| 7 (3+4) | GG2 | Favorable Intermediate |
| 7 (4+3) | GG3 | Unfavorable Intermediate |
| 8 (4+4 / 3+5 / 5+3) | GG4 | High |
| 9 to 10 | GG5 | Very High |
Understanding where your score falls in this chart is the foundation for everything that follows. It is also worth knowing that the same Gleason score can look very different from one patient to the next, depending on PSA level, clinical stage, and tumor volume. The score is a critical piece of the puzzle, but it is never the whole picture.
Gleason Score 6: Low Risk, Favorable Prognosis
A Gleason score of 6 (3+3) is the lowest score assigned in modern pathology for a cancer diagnosis. It indicates well-differentiated cancer cells that generally grow very slowly, and in many patients will never cause symptoms or require active intervention during their lifetime.
Many men with Gleason 6 prostate cancer are candidates for active surveillance rather than immediate treatment. It is now widely accepted in the urologic oncology community that Gleason score 6 cancer has an extremely low metastatic potential when managed appropriately.
Active surveillance does not mean doing nothing. It means committing to a structured monitoring protocol: regular PSA testing, periodic repeat biopsies at defined intervals, and often MRI surveillance to confirm the cancer is not upgrading over time. Patients on surveillance should understand that the goal is to detect meaningful change early, not to defer treatment indefinitely, regardless of what the monitoring reveals.
Gleason Score 7: The Most Important Distinction in Prostate Cancer
A Gleason score 7 sits in what oncologists call the intermediate risk category, but this label obscures a critically important difference that many newly diagnosed patients miss entirely. Not all 7s are the same. The score contains two biologically and clinically distinct subtypes, and the distinction between them carries real consequences for treatment planning, prognosis, and quality of life.
3+4=7 vs. 4+3=7: Why the Order of the Numbers Matters
Gleason 3+4=7 (Grade Group 2, Favorable Intermediate): The dominant pattern is grade 3, meaning the majority of cancer cells are slower-growing and better differentiated. This variant carries a better prognosis, and more patients are candidates for less intensive treatment, compared to unfavorable intermediate (Gleason 4+3) prostate cancer.
Gleason 4+3=7 (Grade Group 3, Unfavorable Intermediate): The dominant pattern is grade 4, indicating a more aggressive cellular architecture. This variant carries a higher recurrence risk after treatment and more commonly requires the addition of androgen deprivation therapy (ADT) alongside local treatment to achieve optimal outcomes.
Gleason Score 8: High-Risk Disease Requiring Aggressive Treatment
A Gleason score 8 (4+4, 3+5, or 5+3) indicates high-risk prostate cancer with predominantly poorly differentiated cells. These tumors carry a meaningful risk of extraprostatic extension, meaning the cancer may have already spread beyond the prostate capsule even when imaging appears negative, and a higher probability of microscopic lymph node involvement that standard imaging cannot detect.
Men with Gleason 8 cancer are not candidates for active surveillance and require more intensive treatment than Gleason 7 cancers. The current standard of care typically involves either radical prostatectomy (potentially followed by radiation) or external beam radiation therapy combined with 18 to 24 months of androgen deprivation ("hormone") therapy.
Gleason Score 9 and 10: Very-High-Risk Disease
Gleason scores of 9 or 10, classified as Grade Group 5, represent the most aggressive category of prostate cancer. These cases require urgent evaluation and management. These tumors behave similarly to Gleason 8, but are even more aggressive. Often multi-modal treatment is indicated including the addition of anti-androgen medications such as abiraterone and prednisone.
Gleason Score and Treatment Options
Treatment decisions are not based on the Gleason score alone. The score is combined with PSA level, clinical staging, biopsy core involvement percentage, and findings from advanced imaging, including MRI and increasingly PSMA PET, to arrive at a risk stratification that drives the treatment conversation. The table below summarizes how risk groups generally map to treatment approaches, though individual recommendations will vary based on the full clinical picture.
| Gleason Score | Risk Category | Common Treatment Approaches |
|---|---|---|
| 6 (3+3) | Low | Active surveillance (recommended), focal therapy, radiation, or surgery |
| 7 (3+4) | Favorable Intermediate | Active surveillance (select patients), focal therapy, radiation, or surgery |
| 7 (4+3) | Unfavorable Intermediate | Focal therapy (select patients), surgery, or radiation plus 4 to 6 months ADT |
| 8 | High | Surgery or radiation plus 18 to 24 months ADT |
| 9 to 10 | Very High | Surgery (often followed by additional radiation) or radiation with 18 to 24 months ADT, often with additional anti-androgen medications |
Taking the Next Step With Confidence
If you or someone you love has recently received a prostate cancer diagnosis, the urologists at Atlanta Prostate Center are here to help you make sense of it. Our team has the clinical experience and the diagnostic technology to give you a complete, accurate picture of your disease and the full range of treatment options to act on it.
